Differential effects of a new central adrenergic
agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers.
Saletu B, Frey R, Krupka M,
Anderer P, Grunberger J, Barbanoj
MJ.
Department of Psychiatry,
University of Vienna, Austria.
Int J Clin Pharmacol Res 1989;9(3):183-95
ABSTRACT
Modafinil is a recently developed central alpha adrenergic agonist with vigilance-promoting properties. In a double-blind, placebo-controlled sleep laboratory study, its single-dose effects on objectively and subjectively evaluated sleep, morning awakening, and early morning behaviour were investigated and compared with amphetamine. Ten young healthy volunteers of both sexes spent 12 nights in the sleep laboratory: one adaptation night, one baseline night, five drug nights (100 mg and 200 mg modafinil; 10 mg and 20 mg d-amphetamine; placebo) and five subsequent washout nights.
The drugs were administered in one week intervals according to a Latin square design. Somnopolygraphic investigations were performed between 22h30 and 06h00.
Subjects received the drug orally half an hour before bedtime. A self-rating scale for sleep and awakening quality and early morning behavior was completed subsequent to the morning toilet. Thereafter, noopsychic and thymopsychic variables were evaluated utilizing a psychometric test-battery.
Statistical analyses of objective sleep variables demonstrated that modafinil causes no significant changes as compared to a placebo.
Sleep initiation remained unchanged after all of the drugs, while sleep maintenance was impaired dose-dependently after d-amphetamine. Thus, total sleep time and sleep efficiency decreased significantly after 20 mg d-amphetamine as compared to the placebo and modafinil. In regard to sleep architecture a reduction of sleep stage 2 and rapid eye movement-sleep occurred under d-amphetamine while modafinil did not exhibit such an effect.
Subjective sleep quality was significantly better after modafinil than after the reference compound. Subjective awakening quality and well-being in the morning did not show any significant findings.
Furthermore, no differences were observed between the placebo and the other drugs concerning objective awakening quality (evaluated by psychometric tests).
Critical flicker frequency increased significantly after 20 mg d-amphetamine as compared to the placebo.
Pulse rate and evening and morning blood pressure remained unchanged. These data stress the necessity to differentiate between "vigility-increasing" properties of amphetamine and "vigilance-promoting" properties of modafinil.
1. modafinil is
a potential treatment for
fibromyalgia
2. modafinil improves
fatigue in patients with multiple sclerosis
3. modafinil offers
promise as an augmentation to antidepressants
4. modafinil excessive sleepiness in
Parkinson's disease
5. modafinil excessive
daytime sleepiness in Parkinson's disease
6. modafinil may
be useful for attention-deficit/hyperactivity disorder
7. modafinil benefits
cerebral palsy in an unknown way
8. modafinil
article
9. modafinil
amplification of cortical serotonin release
10. modafinil
treatment of alcoholic organic brain syndrome
11. modafinil
effect on melatonin, cortisol, and growth hormone
12. modafinil
in obstructive sleep apnea-hypopnea syndrome
13. modafinil
vs dextroamphetamine in treatment of adult ADHD
14. modafinil
efficacy in narcolepsy
15. modafinil
switching from narcolepsy drugs to modafinil
16. modafinil
drug of choice for narcolepsy
17. modafinil
dopaminergic transmission mediates CNS stimulants
18. modafinil
for daytime sleepiness in sleep apnea
19. modafinil
treatment of residual excessive daytime sleepiness
20. modafinil
in the treatment of
narcolepsy
21. modafinil
and naps as counter measures in sleep deprivation
22. modafinil
effect on narcolepsy
23. modafinil
as a treatment for excessive daytime sleepiness
24. modafinil
a narcolepsy study
25. modafinil
use in a sleep deprivation experiment
26. modafinil for
sustaining the alertness of helicopter pilots
27. modafinil the
unique properties of a new stimulant
28. modafinil dosage
and safety
29. modafinil in treatment of fatigue in
multiple sclerosis
30. modafinil non-addictive potential of modafinil
31. modafinil successful
treatment of hypersomnia & narcolepsy
32. modafinil physiological effects of modafinil in drug abusers
33. modafinil narcolepsy:
symptoms and management
34. modafinil cognitive enhancing effects of modafinil
